, Tumor Microenvironment and Metastasis Program (TMM) The Tumor Microenvironment and Metastasis Program (TMM) is a highly interactive Program in which members combine basic, fundamental research expertise to understand the biology of cancer cell autonomous effects in relation to paracrine actions and specific components of the tumor microenvironment (TME) within the primary tumor and at distant metastatic sites and to study the systemic effects of those interactions. The basic work of TMM in predominately ?solid? tumors mirrors the basic research in ?liquid tumors? conducted by HHM which provides the backdrop for translating their findings into the clinic through collaborations with the clinical and translational members of EDT and CPC. Understanding the factors released by the TME into the systemic circulation will provide novel diagnostic strategies, whereas understanding how the TME nurtures cancer cells to enhance invasion and the respective clinical sequelae, will lead to new cancer prevention and treatment strategies. The goals of TMM are to translate discoveries of the pathobiology of solid tumors, the TME, and systemic effects of metastases into new cancer targets and novel therapies, so as to prevent metastases and sequelae. TMM advances this vision by focusing on two overarching themes: Theme 1 is focused on cancer cell-stroma interactions and their roles in cancer initiation, progression, and metastasis. These interactions involve TME components such as cancer-associated fibroblasts, myeloid derived suppressor cells, macrophages, T and B lymphocytes and the extracellular matrix; Theme 2 encompasses the systemic effects of metastases and the mechanisms that contribute to perturbations in muscle, bone and cognitive functions and respective clinical sequelae. During the past five years, there have been several notable successes, including the funding of a SPORE in hyperactive Ras signaling led by work of Dr. Wade Clapp, further development of working groups in cancers of the pancreas, ovary, and prostate, resulting in increased funding in these areas; and new insight into musculoskeletal effects of cancer metastasis. Several members from the former Breast Cancer Program were incorporated into TMM to enhance research expertise in solid cancers. Retreats foster focused, in depth collaborations. TMM has hosted visiting experts and recruited faculty members with expertise based on needs identified at the annual retreats. TMM has 28 Full and 8 Associate Members, representing 17 Departments and 5 Schools on the campuses of Indiana University School of Medicine, Indiana University- Purdue University Indianapolis (IUPUI), and IU Bloomington. The Program has $9.1M in total direct funding (20% increase since 2013), and $6.8M in peer-reviewed funding, with $2.4M from the NCI and $1.8M from other NIH Institutes. Over the past funding period, TMM members have authored 394 publications (18% intra- programmatic, 26% inter-programmatic, and 64% inter-institutional collaborations) and have 17 multi-PI grants including six inter-institutional and eight inter-programmatic (EDT-5, HHM-2 and CPC-1) reflecting strong collaborations through local, national and international networking.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082709-20
Application #
9793164
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Pin, Fabrizio; Barreto, Rafael; Kitase, Yukiko et al. (2018) Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle 9:685-700
Robertson, Michael J; Stamatkin, Christopher W; Pelloso, David et al. (2018) A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. J Immunother 41:151-157
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10

Showing the most recent 10 out of 256 publications